TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
CVS Pharmacy and several subsidiaries agreed to pay $315 million to settle a Justice Department lawsuit alleging they unlawfully filled medically unnecessary opioid and other controlled-substance prescriptions. CVS disputes the allegations, and the settlement does not admit wrongdoing; it also requires additional safeguards for dispensing controlled substances.
CVS Pharmacy and several subsidiaries have agreed to pay $315 million to resolve a Justice Department lawsuit alleging the company unlawfully dispensed medically unnecessary opioid and other controlled-substance prescriptions. The settlement also requires additional safeguards for dispensing those medications; CVS disputes the allegations and says the deal includes no admission of wrongdoing.
The agreement resolves a lawsuit filed in 2024 under the Controlled Substances Act. The Justice Department alleged that CVS filled illegitimate prescriptions, including prescriptions for high doses of potent opioids, and dispensed large quantities of drugs based on orders from providers it described as “pill mills”—providers alleged to issue prescriptions without a legitimate medical purpose.
The department also alleged that staffing levels, performance metrics and incentive compensation policies contributed to pharmacists filling prescriptions without adequately confirming their legitimacy. According to the lawsuit, many of the prescriptions were billed to and reimbursed by Medicaid and other federal health programs. Those points are allegations in the government’s case, not findings established by the settlement.
Alongside the payment, CVS must put in place additional safeguards so prescriptions for opioids and other controlled substances are dispensed only when medically appropriate, Assistant Attorney General Brett Shumate said. The source report did not specify how the $315 million will be distributed or provide a timetable for implementing the safeguards.
New Federal Oversight of CVS Dispensing
The agreement combines a substantial payment with changes to how a major pharmacy chain handles controlled-substance prescriptions. The new safeguards are intended to address the Justice Department’s concerns about whether prescriptions were medically appropriate before they were filled. Their practical effect will depend on the terms and implementation, details of which were not provided in the report.
The case also concerns prescriptions allegedly reimbursed by Medicaid and other federal programs, linking pharmacy dispensing practices to public spending as well as patient safety. Federal officials described the agreement as part of efforts to hold companies accountable for conduct they allege contributed to the U.S. addiction and overdose crisis. The settlement resolves the government’s claims against CVS without the company admitting liability.
pill organizer for medication management
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
The 2024 Lawsuit and Earlier Deals
The Justice Department brought its case in 2024, alleging CVS violated the Controlled Substances Act by filling prescriptions that were not issued for legitimate medical purposes. The government said the prescriptions included high doses of potent opioids and claimed the company’s operating practices made it harder for pharmacists to identify questionable orders.
CVS said in 2024 that pharmacists were being judged under “vague, undefined, and ever-changing standards of practice” for filling opioid prescriptions. The settlement comes after a decade of opioid-related agreements involving drugmakers, wholesalers, pharmacies and other companies. The report says those settlements total more than $50 billion across U.S. governments, with most of the agreements and money involving state and local governments. Walgreens and Walmart have also reached federal deals in the past two years, according to the report.
The broader crisis has been linked to more than 100,000 U.S. deaths in some years, although the report says death counts have fallen sharply recently. It does not give specific years, figures or a breakdown of how the CVS settlement compares with other agreements.
““Today’s settlement is a significant milestone in the Justice Department’s efforts to combat the opioid epidemic by cracking down on pharmacies who unlawfully fulfill prescriptions for controlled substances.””
— Associate Attorney General Stanley Woodward
As an affiliate, we earn on qualifying purchases.
Settlement Terms Still Unspecified
The available report does not describe the payment schedule, how the money will be allocated, or how the required safeguards will be monitored. It is also unclear when the changes must be fully in place and what consequences could follow if CVS fails to meet the agreement’s requirements.
The settlement resolves the lawsuit, but the reported details do not include a full account of its legal terms. The Justice Department’s claims about unlawful prescriptions, staffing and performance incentives remain government allegations; CVS has rejected the claims, and the agreement does not include an admission of wrongdoing.
As an affiliate, we earn on qualifying purchases.
Implementation and Federal Monitoring
The next steps are for CVS to carry out the additional dispensing safeguards required by the agreement and for the Justice Department and other relevant authorities to oversee compliance under the settlement’s terms. The source report provides no implementation deadlines or monitoring schedule, so those details remain to be clarified.
Further information on the payment’s timing and distribution may also clarify how the agreement will be administered. For now, the confirmed development is that CVS has agreed to pay $315 million and change its safeguards, while continuing to dispute the allegations that prompted the case.
controlled substance prescription monitor
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
How much will CVS pay?
CVS Pharmacy and several subsidiaries agreed to pay $315 million to resolve the Justice Department case. The report does not specify the payment schedule or how the money will be distributed.
What did the Justice Department allege?
The department alleged that CVS unlawfully filled medically unnecessary prescriptions for opioids and other controlled substances, including prescriptions from providers it described as pill mills. It also alleged that company staffing and performance practices contributed to inadequate checks. These are allegations, not findings established by the settlement.
Did CVS admit wrongdoing?
No. CVS said it strongly disagrees with the lawsuit’s claims and that the settlement admits no wrongdoing.
What changes does the settlement require?
CVS must implement additional safeguards so opioid and other controlled-substance prescriptions are dispensed only when medically appropriate. The report does not give a deadline or describe the safeguards in detail.
When was the lawsuit filed?
The Justice Department filed the lawsuit in 2024. The settlement was announced October 13, 2026, according to the source report.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
